- Home
- Publications
- Publication Search
- Publication Details
Title
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer
Authors
Keywords
-
Journal
JNCI-Journal of the National Cancer Institute
Volume 109, Issue 12, Pages -
Publisher
Oxford University Press (OUP)
Online
2017-04-13
DOI
10.1093/jnci/djx089
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)
- (2017) Alexander Drilon et al. Cancer Discovery
- Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target
- (2016) E. Yakirevich et al. CLINICAL CANCER RESEARCH
- Identification of neutral tumor evolution across cancer types
- (2016) Marc J Williams et al. NATURE GENETICS
- Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer
- (2016) Andrew Rankin et al. ONCOLOGIST
- Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer
- (2016) R. Moretto et al. ONCOLOGIST
- Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer
- (2015) Alessio Amatu et al. BRITISH JOURNAL OF CANCER
- Chromosomal rearrangements involving the NTRK1 gene in colorectal carcinoma
- (2015) Laurent Créancier et al. CANCER LETTERS
- Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis
- (2015) Filippo Pietrantonio et al. EUROPEAN JOURNAL OF CANCER
- The distribution ofBRAFgene fusions in solid tumors and response to targeted therapy
- (2015) Jeffrey S. Ross et al. INTERNATIONAL JOURNAL OF CANCER
- Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer
- (2015) Andrea Sartore-Bianchi et al. JNCI-Journal of the National Cancer Institute
- FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
- (2015) Chiara Cremolini et al. LANCET ONCOLOGY
- Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF
- (2015) J. F. Hechtman et al. MOLECULAR CANCER RESEARCH
- The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets
- (2015) Enzo Medico et al. Nature Communications
- Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer
- (2015) M. Russo et al. Cancer Discovery
- Identification and characterization of RET fusions in advanced colorectal cancer
- (2015) Anne-France Le Rolle et al. Oncotarget
- Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening
- (2015) Jeeyun Lee et al. Oncotarget
- NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line
- (2015) Su Jin Lee et al. Oncotarget
- ALK and ROS1 Overexpression is Very Rare in Colorectal Adenocarcinoma
- (2015) Michelle Houang et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy
- (2015) Mihaela Angelova et al. GENOME BIOLOGY
- Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer
- (2015) Andrea Sartore-Bianchi et al. JNCI-Journal of the National Cancer Institute
- Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies
- (2014) S. Venderbosch et al. CLINICAL CANCER RESEARCH
- The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition
- (2014) Elena Ardini et al. Molecular Oncology
- RNF43 is frequently mutated in colorectal and endometrial cancers
- (2014) Marios Giannakis et al. NATURE GENETICS
- The landscape of kinase fusions in cancer
- (2014) Nicolas Stransky et al. Nature Communications
- ROS1 and ALK Fusions in Colorectal Cancer, with Evidence of Intratumoral Heterogeneity for Molecular Drivers
- (2013) Dara L. Aisner et al. MOLECULAR CANCER RESEARCH
- Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum
- (2012) Mai Yamauchi et al. GUT
- Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies
- (2012) Doron Lipson et al. NATURE MEDICINE
- Exon Array Profiling Detects EML4-ALK Fusion in Breast, Colorectal, and Non-Small Cell Lung Cancers
- (2009) E. Lin et al. MOLECULAR CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More